Observational studyRheumatology (Oxford, England)2025
Genetically-determined variation in CRP impacts disease activity assessment in rheumatoid arthritis.
Observational study in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Plasma Proteomics Identifies Thousand-and-One-Amino Acid Kinase 3 as a Potential Biomarker of Rheumatoid Arthritis Activity and a Novel Therapeutic Target.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- Heterogeneity in the association of genetic risk for RA and resultant RA phenotypes.Rheumatology (Oxford, England) · 2026Article
- Within-individual variation of C-reactive protein (CRP) measurements in primary care: A retrospective cohort study.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
objectivesIn patients with RA, we evaluated a single-nucleotide variant previously associated with lower CRP to assess if this impacts clinical disease activity assessments including the disease activity score-28 with CRP (DAS28(CRP)).
methodsPatients from three observational cohorts were evaluated-the United Kingdom Biobank (UKB), the Veterans Affairs RA Registry (VARA) and the FORWARD Databank. The effect of rs1205 genotype on log-adjusted serum CRP concentrations was assessed using linear regression adjusted for sex, age and population structure. The regression coefficients from UKB were converted to create a modified CRP and DAS28(CRP). Reclassification to an abnormal CRP (>0.8 mg/dl) and between DAS28(CRP) disease activity groups were determined.
resultsAmong the 488 377 UKB participants, individuals with the TT and CT genotype had a statistically significantly lower log-adjusted CRP compared with the CC genotype [β TT genotype: -0.371 (95% CI -0.381, -0.360), P < 0.001; β CT genotype: -0.173 (95% CI -0.179, -0.167), P < 0.001]. In the 2597 VARA participants, the DAS28(CRP) was significantly lower in the genotype TT compared with the CC genotype [β -0.22, (95% CI -0.44, -0.0027), P = 0.047], but not in the CT genotype. In those with the TT genotype, 6-8% were reclassified to having an abnormal CRP and 3% of patients were reclassified from low to moderate disease activity.
conclusionThe rs1205 TT genotype in CRP is associated with lower CRP and DAS28(CRP). Given the widespread use of CRP, this demonstrates that genetic factors, irrespective of an individual patient's disease activity, can cause differences in CRP that impact disease activity assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.